SUNPHARMA Stock View

Sun Pharmaceutical Industries Ltd
stock-view-header

₹ 1,146.15

icon -12.05 | -1.05
Market Cap ₹( Cr.)
2,749,998.00
Proj. P/E (x)
29.40
Proj. P/BV (x)
4.56
Proj. ROE (%)
15.48
Proj EV / EBITDA (x)
--
Proj. Revenue ( Cr.)
488,066.24

Stock View

BUY

Last Updated On.
17-Sep-2023
 

The average score for Sun Pharmaceutical Industries Ltd stands at 8 against 9, three months back.

Sun Pharmaceutical Industries Limited is an India-based specialty generic pharmaceutical company. The Company is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulation and active pharmaceutical ingredients (APIs). It produces a comprehensive, diverse and complementary portfolio of generic and specialty medicines targeting a wide spectrum of chronic and acute treatments. The Company's vertically integrated network enables it to produce a wide range of pharmaceuticals, including oncology, hormones, peptides, and steroidal drugs. The Company also has a product portfolio in RoW markets, including injectables, hospital products and retail products. It offers a variety of dosage forms, including orals, creams, ointments, injectables, sprays, and liquids. Its marketed specialty portfolio includes Ilumya/ Ilumetri, Winlevi, Levulan Kerastick + BLU-U, Absorica LD, Odomzo, Cequa, Bromsite, Xelpros, Yonsa, Sezaby and Sprinkle portfolio.

Disclaimer : All estimates (1 year forward) are based on Consensus View provided by Refinitiv.


Technical Data

50 DMA(₹)
1,124.59
100 DMA(₹)
1,055.17
200 DMA(₹)
1,026.23
52 Weeks Range
891.60     1,169.90

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required